Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Protocol # 20-577

Status

Recruiting

Description

This is an open-label, FIH study designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-4008, a potent and highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor administered orally patients with unresectable or metastatic ICC and other unresectable or metastatic solid tumors. This study consists of 2 parts, a dose escalation (Part 1) and a dose expansion (Part 2).

Condition

  • FGFR2 Amplification
  • FGFR2 Gene Mutation
  • FGFR2 Gene Rearrangement
  • FGFR2 Gene Translocation
  • FGFR2 Gene Activation
  • Intrahepatic Cholangiocarcinoma
  • Cholangiocarcinoma
  • Other Solid Tumors, Adult

Interventions

  • RLY-4008

Phase

Phase 1

Study Type

Interventional

Further Study Details

Primary Outcome:

  • Determination of maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RLY-4008
  • Number of patients with adverse events and serious adverse events

Secondary Outcome:

  • FGFR2 gene status in plasma circulating tumor deoxyribonucleic acid (ctDNA) and tumor tissue
  • Overall response rate (ORR) as assessed by RECIST v1.1
  • Duration of Response (DOR) as assessed by RECIST v1.1
  • Disease Control Rate (DCR) as assessed by RECIST v1.1
  • Pharmacokinetic parameters including maximum plasma drug concentration (Cmax)
  • Pharmacokinetic parameters including area under the plasma concentration versus time curve from time 0 to 24 hours postdose (AUC0-24)
  • Pharmacokinetic parameters including terminal elimination half-life (t1/2)
  • Pharmacodynamic parameters including changes in fibroblast growth factor 23 (FGF-23)
  • Pharmacodynamic parameters including changes in carcinoembryonic antigen (CEA)
  • Pharmacodynamic parameters including changes in cancer antigen 19-9 (CA 19-9)

Enrollment

200

Study Start Date

September 2, 2020

Eligibility

  • Gender:     All
  • Minimum age:     18 Years
  • Maximum age:     N/A
  • Healthy volunteers:     No

Sponsors

Relay Therapeutics, Inc.

Source

Relay Therapeutics, Inc.

Official title

A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors

Clinicaltrials.gov Identifier

NCT04526106

     

Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.